Axogen Forecasts At Least $270M in 2026 Revenue with 20% Growth Amid Avance Biologic Transition

Axogen (NASDAQ:AXGN) reported Q1 2026 revenue of $61.5 million and Adjusted EBITDA of $5.7 million, with management raising full-year guidance due to strong growth across target markets. The company expects at least $270 million in revenue by 2026, driven by a 20% growth rate and progress in expanding commercial insurance coverage.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · April 28, 2026, 21:42 UTC

Tickers: $AXGN

Topics: earnings call EBITDA financial performance guidance update revenue growth

Read the full article at Seeking Alpha

More World news

EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC